collection
MENU ▼
Read by QxMD icon Read
search

Breast

shared collection
8 papers 0 to 25 followers
By Saadvik Raghuram Mbbs graduate, persuing radiation oncology
https://www.readbyqxmd.com/read/26617202/taxanes-versus-s-1-as-the-first-line-chemotherapy-for-metastatic-breast-cancer-select-bc-an-open-label-non-inferiority-randomised-phase-3-trial
#1
RANDOMIZED CONTROLLED TRIAL
Tsutomu Takashima, Hirofumi Mukai, Fumikata Hara, Nobuaki Matsubara, Tsuyoshi Saito, Toshimi Takano, Youngjin Park, Tatsuya Toyama, Yasuo Hozumi, Junji Tsurutani, Shigeru Imoto, Takanori Watanabe, Yoshiaki Sagara, Reiki Nishimura, Kojiro Shimozuma, Yasuo Ohashi
BACKGROUND: Oral fluoropyrimidines are used for the first-line treatment of metastatic breast cancer to avoid severe adverse effects, although firm supporting evidence is lacking. We aimed to establish whether S-1 is non-inferior to taxanes in this setting. METHODS: We did an open-label, non-inferiority, phase 3 trial at 154 hospitals in Japan. We enrolled individuals who had HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease, and who were resistant to endocrine treatment...
January 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27425375/partial-breast-irradiation-for-early-breast-cancer
#2
REVIEW
Brigid E Hickey, Margot Lehman, Daniel P Francis, Adrienne M See
BACKGROUND: Breast-conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by radiotherapy (RT). RT is given to sterilize tumour cells that may remain after surgery to decrease the risk of local tumour recurrence. Most true recurrences occur in the same quadrant as the original tumour. Whole breast radiotherapy (WBRT) may not protect against the development of a new primary cancer developing in other quadrants of the breast...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27422584/gec-estro-multicenter-phase-3-trial-accelerated-partial-breast-irradiation-with-interstitial-multicatheter-brachytherapy-versus-external-beam-whole-breast-irradiation-early-toxicity-and-patient-compliance
#3
Oliver J Ott, Vratislav Strnad, Guido Hildebrandt, Daniela Kauer-Dorner, Hellen Knauerhase, Tibor Major, Jaroslaw Łyczek, José Luis Guinot, Jürgen Dunst, Cristina Gutierrez Miguelez, Pavel Slampa, Michael Allgäuer, Kristina Lössl, Bülent Polat, György Kovács, Arnt-René Fischedick, Thomas G Wendt, Rainer Fietkau, Rolf-Dieter Kortmann, Alexandra Resch, Anna Kulik, Leo Arribas, Peter Niehoff, Ferran Guedea, Annika Schlamann, Richard Pötter, Christine Gall, Martina Malzer, Wolfgang Uter, Csaba Polgár
BACKGROUND AND PURPOSE: To compare early side effects and patient compliance of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to external beam whole breast irradiation (WBI) in a low-risk group of patients with breast cancer. MATERIAL AND METHODS: Between April 2004 and July 2009, 1328 patients with UICC stage 0-IIA breast cancer were randomized to receive WBI with 50Gy and a boost of 10Gy or APBI with either 32.0Gy/8 fractions, or 30...
July 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27403017/incidental-irradiation-of-internal-mammary-lymph-nodes-in-breast-cancer-conventional-two-dimensional-radiotherapy-versus-conformal-three-dimensional-radiotherapy
#4
Elton Trigo Teixeira Leite, Rafael Tsuneki Ugino, Marco Antônio Santana, Denis Vasconcelos Ferreira, Maurício Russo Lopes, Edilson Lopes Pelosi, João Luis Fernandes da Silva, Heloisa de Andrade Carvalho
OBJECTIVE: To evaluate incidental irradiation of the internal mammary lymph nodes (IMLNs) through opposed tangential fields with conventional two-dimensional (2D) or three-dimensional (3D) radiotherapy techniques and to compare the results between the two techniques. MATERIALS AND METHODS: This was a retrospective study of 80 breast cancer patients in whom radiotherapy of the IMLNs was not indicated: 40 underwent 2D radiotherapy with computed tomography for dosimetric control, and 40 underwent 3D radiotherapy...
May 2016: Radiologia Brasileira
https://www.readbyqxmd.com/read/27116013/photobiomodulation-for-the-management-of-radiation-dermatitis-the-dermis-trial-a-pilot-study-of-mls-%C3%A2-laser-therapy-in-breast-cancer-patients
#5
Sandrine Censabella, Stefan Claes, Jolien Robijns, Paul Bulens, Jeroen Mebis
PURPOSE: The aim of this study was to assess the effectiveness and acceptability of photobiomodulation using MLS(®) laser therapy (LT) in the management of acute radiation dermatitis (RD). METHODS: We compared two successive groups of breast cancer patients undergoing identical radiotherapy regimens post-lumpectomy. Both groups received our standard skin care but the second group received six additional LT sessions (beam area 19.635 cm(2), 0.168 W/cm(2), 4 J/cm(2)), starting at fraction 20 of radiotherapy (control and LT group, N = 41 and 38, respectively)...
September 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/24055415/the-uk-standardisation-of-breast-radiotherapy-start-trials-of-radiotherapy-hypofractionation-for-treatment-of-early-breast-cancer-10-year-follow-up-results-of-two-randomised-controlled-trials
#6
RANDOMIZED CONTROLLED TRIAL
Joanne S Haviland, J Roger Owen, John A Dewar, Rajiv K Agrawal, Jane Barrett, Peter J Barrett-Lee, H Jane Dobbs, Penelope Hopwood, Pat A Lawton, Brian J Magee, Judith Mills, Sandra Simmons, Mark A Sydenham, Karen Venables, Judith M Bliss, John R Yarnold
BACKGROUND: 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer. In this prespecified analysis, we report the 10-year follow-up of the START trials testing 13 fraction and 15 fraction regimens. METHODS: From 1999 to 2002, women with completely excised invasive breast cancer (pT1-3a, pN0-1, M0) were enrolled from 35 UK radiotherapy centres...
October 2013: Lancet Oncology
https://www.readbyqxmd.com/read/27046390/acute-skin-toxicity-associated-with-a-1-week-schedule-of-whole-breast-radiotherapy-compared-with-a-standard-3-week-regimen-delivered-in-the-uk-fast-forward-trial
#7
A Murray Brunt, Duncan Wheatley, John Yarnold, Navita Somaiah, Stephen Kelly, Adrian Harnett, Charlotte Coles, Andrew Goodman, Amit Bahl, Mark Churn, Rada Zotova, Mark Sydenham, Clare L Griffin, James P Morden, Judith M Bliss
BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions. MATERIAL AND METHODS: Patients were randomly allocated to 40Gy/15 fractions (F)/3-weeks, 27Gy/5F/1-week or 26Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4...
July 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27044936/absolute-benefit-of-adjuvant-endocrine-therapies-for-premenopausal-women-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-early-breast-cancer-text-and-soft-trials
#8
Meredith M Regan, Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Giuseppe Viale, Marco Colleoni, István Láng, Henry L Gómez, Carlo Tondini, Graziella Pinotti, Karen N Price, Alan S Coates, Aron Goldhirsch, Richard D Gelber
PURPOSE: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breast cancer, testing exemestane plus ovarian function suppression (OFS), tamoxifen plus OFS, and tamoxifen alone. We examined absolute treatment effect across a continuum of recurrence risk to individualize endocrine therapy decision making for premenopausal women with human epidermal growth factor receptor 2 (HER2) -negative disease...
July 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"